Outlook Therapeutics OTLK
NASDAQ OTLK
$0.56 +0.04 (+7.94%)
At close: Oct 21, 2026 · 4:00 PM EDT

Outlook Therapeutics (OTLK) EBITDA Margin (2015 - 2025)

Updated

Outlook Therapeutics' EBITDA Margin came in at -4735.97% for FY2025 (year ended Sep 30, 2025).

Analysis

Outlook Therapeutics (OTLK) EBITDA Margin (2015 - 2025) Analysis & Trends

Going back to FY2015, Outlook Therapeutics' EBITDA Margin data covers 6 fiscal years.

  • The FY2025 figure represents the highest annual EBITDA Margin in data going back to FY2015.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 53.49%
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 35.95%
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 49.01%
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 6.02%
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 33.11%
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 46.01%
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -124.26%
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 39.16%
10 Outlook Therapeutics 77.51 Mn 41.76 Mn -8,265.00 -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 -1,044.25%
Dec 31, 2024 -138,445.09%
Jun 30, 2024 -5,627.84%
Dec 31, 2023 -5,383.67%
Sep 30, 2023 -4,181.38%
Jun 30, 2023 -4,639.62%
Mar 31, 2023 -3,996.35%
Sep 30, 2021 -11,170.42%
Sep 30, 2019 -201.64%
Jun 30, 2019 -823.98%
Mar 31, 2019 -1,074.51%
Dec 31, 2018 -883.69%
Sep 30, 2018 -1,501.41%
Jun 30, 2018 -828.85%
Mar 31, 2018 -790.23%
Dec 31, 2017 -324.29%
Sep 30, 2017 -77.20%
Jun 30, 2017 -2,198.43%
Mar 31, 2017 -2,361.23%
Dec 31, 2016 -5,649.36%
API Access

Outlook Therapeutics EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=OTLK&period=max&api_key=YOUR_API_KEY